Tritec is a drug owned by Glaxosmithkline. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 13, 2014. Details of Tritec's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5629297 | Medicament for treating gastrointestinal disorders |
May, 2014
(10 years ago) |
Expired
|
| US5601848 | Methods for the treatment of gastrointestinal disorders |
Feb, 2014
(10 years ago) |
Expired
|
| US5456925 | Pharmaceutical compositions containing furan derivatives |
Oct, 2012
(12 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Tritec is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tritec's family patents as well as insights into ongoing legal events on those patents.
Tritec's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tritec's generic launch date based on the expiry of its last outstanding patent is estimated to be May 13, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tritec Generics:
There are no approved generic versions for Tritec as of now.
About Tritec
Tritec is a drug owned by Glaxosmithkline. It is used for treating gastrointestinal disorders caused by H. pylori and peptic ulcer disease caused by C. pyloridis through the administration of ranitidine bismuth citrate, clarithromycin, and bismuth. Tritec uses Ranitidine Bismuth Citrate as an active ingredient. Tritec was launched by Glaxosmithkline in 1996.
Approval Date:
Tritec was approved by FDA for market use on 08 August, 1996.
Active Ingredient:
Tritec uses Ranitidine Bismuth Citrate as the active ingredient. Check out other Drugs and Companies using Ranitidine Bismuth Citrate ingredient
Treatment:
Tritec is used for treating gastrointestinal disorders caused by H. pylori and peptic ulcer disease caused by C. pyloridis through the administration of ranitidine bismuth citrate, clarithromycin, and bismuth.
Dosage:
Tritec is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 400MG | TABLET | Discontinued | ORAL |